BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

The primary focus in scaling up production should first be the adoption of lean manufacturing principles used in virtually ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Josh Ludwig is global commercial director at ScaleReady, where he leads a team of scientists that drives new business through ...